ProKidney Corp [PROK] stock is trading at $2.09, up 19.43%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PROK shares have gain 42.18% over the last week, with a monthly amount glided 53.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, BofA Securities downgraded its rating to Neutral on January 02, 2024. On July 25, 2023, BTIG Research initiated with a Buy rating and assigned a price target of $16 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $15 on December 21, 2022. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $13 as its price target on November 10, 2022. UBS started tracking with a Buy rating for this stock on October 18, 2022, and assigned it a price target of $18. In a note dated October 14, 2022, Citigroup initiated an Buy rating and provided a target price of $16 on this stock.
ProKidney Corp [PROK] stock has fluctuated between $1.12 and $13.51 over the past year. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. ProKidney Corp [NASDAQ: PROK] shares were valued at $2.09 at the most recent close of the market. An investor can expect a potential return of 617.7% based on the average PROK price forecast.
Analyzing the PROK fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is 0.06 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7100 points at the first support level, and at 1.3300 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.4500, and for the 2nd resistance point, it is at 2.8100.
Ratios To Look Out For
For context, ProKidney Corp’s Current Ratio is 14.94. In addition, the Quick Ratio stands at 14.94 and the Cash Ratio stands at 2.42.
Transactions by insiders
Recent insider trading involved Palihapitiya Chamath, Former 10% Owner, that happened on Nov 19 ’23 when 7.26 million shares were sold. 10% Owner, Palihapitiya Chamath completed a deal on Nov 17 ’23 to sell 0.26 million shares. Meanwhile, 10% Owner Palihapitiya Chamath sold 0.21 million shares on Nov 16 ’23.
